ITEMS IN AFP WITH KEYWORD:
Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a heterogeneous group of conditions related to biologic and cellular abnormalities. Psychological factors do not cause IBS, but many people with IBS also have anxious or depressed mood, prior adverse life events, or psychosocial stressors. Physicians should understand the concerns and expectations of patients and the models the patients use to explain their illness and should empathetically respond to psychosocial cues. Anxiety related to the unpredictability of symptoms may have a greater effect on quality of life than the symptoms themselves. Treatments should focus on symptom relief and improved quality of life.
IBSchek is a blood test marketed to assist in the diagnosis of irritable bowel syndrome with predominant diarrhea (IBS-D) or with mixed bowel habits (IBS-M) in adults.
Gas, bloating, and belching are primarily caused by functional gastrointestinal disorders; psychological distress can make symptoms worse. Exhaustive testing is not necessary for diagnosis. Most patients are classified as having gastric or small bowel bloating, bloating with constipation, or belching disorders. Patients with symptoms of irritable bowel syndrome should be tested for celiac disease; patients with chronic constipation should have a rectal examination. There is insufficient evidence to support the routine use of highly restrictive exclusion diets except in patients with confirmed celiac disease.
The evidence is conflicting on whether gluten-free diets improve symptoms of IBS. Gluten-free diets may improve symptoms such as abdominal pain, stool consistency, and tiredness, and they can be recommended to patients with IBS.
Rifaximin has good overall tolerability. A relatively short course of treatment results in sustained clinical benefit for at least 10 weeks, eliminating the need for continued therapy, with an NNT of 10. However, it is expensive and should be reserved for patients who cannot tolerate or did not respond to more affordable therapies.
Nov 1, 2015 Issue
Effectiveness of Selective Serotonin Reuptake Inhibitors for Irritable Bowel Syndrome [Medicine by the Numbers]
Studies show that 1 in 4 had improved bloating and stool consistency, and less interference with daily life, while only 1 in 9 experiences medication related adverse effects. Want to know more?
Antidepressants and psychological therapies are effective in treating the symptoms of IBS. This study, an update of a similar systematic review and meta-analysis completed five years ago, found the same level of effectiveness for both treatment approaches as the previous analysis, despite 14 new studies that have been published in the interim.
Irritable bowel syndrome is defined as abdominal discomfort or pain associated with altered bowel habits for at least three days per month in the previous three months, with the absence of organic disease. In North America, the prevalence of irritable bowel syndrome is 5 to 10 percent with peak prev...
Jun 15, 2009 Issue
ACG Releases Recommendations on the Management of Irritable Bowel Syndrome [Practice Guidelines]
Irritable bowl syndrome (IBS) is a common disorder characterized by abdominal discomfort and altered bowel function. The American College of Gastroenterology (ACG) performed a series of systematic reviews, and developed evidence-based recommendations for the management of IBS.
Irritable bowel syndrome affects 10 to 15 percent of the U.S. population to some degree. This condition is defined as abdominal pain and discomfort with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical explanation for these symptoms. Irritable bowel syndrome ...